Takeda secures FDA approval for oral orexin agonist Orzeyful in US market

USA— The US Food and Drug Administration (FDA) has approved Takeda’s oral orexin receptor agonist, oveporexton, to treat narcolepsy type 1, introducing the first disease-modifying therapy for the rare neurological sleep disorder.

The drug, which will be marketed as Orzeyful, is expected to become available to eligible patients in the United States once it receives a controlled substance classification from the Drug Enforcement Administration (DEA).

Narcolepsy type 1 is a lifelong condition marked by excessive daytime sleepiness, sudden episodes of muscle weakness known as cataplexy, disrupted nighttime sleep, hallucinations and sleep paralysis.

Current treatments primarily focus on managing individual symptoms rather than addressing the underlying cause of the disease.

Clinical trial results support approval

The FDA based its decision on findings from the Phase III FirstLight (NCT06470828) and RadiantLight (NCT06505031) clinical trials.

In both studies, patients treated with Orzeyful remained awake for longer during the day than those who received a placebo.

The therapy also significantly improved several other symptoms, including nighttime sleep disturbances, hallucinations, and sleep paralysis.

The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.

Targeting the underlying cause

Unlike existing medicines that relieve symptoms, Orzeyful targets the biological cause of narcolepsy type 1.

The therapy activates the orexin receptor 2 (OX2R), which regulates wakefulness and normal sleep-wake cycles.

By stimulating this receptor, the drug compensates for the loss of orexin-producing nerve cells, a defining feature of the disease.

Takeda now plans to obtain DEA scheduling, which it expects within 90 days.

Once the classification is granted, the company intends to distribute Orzeyful through specialty pharmacies across the US.

Competition builds in the orexin receptor market

Orzeyful becomes the first FDA-approved disease-modifying therapy for narcolepsy type 1, a development that sleep medicine specialists have described as a major advance.

Before the approval, GlobalData identified the drug as one of the most important expected regulatory decisions of the third quarter of 2026 because of its potential to reshape treatment for the condition.

Despite Takeda’s first-to-market advantage, competition in the orexin receptor agonist class is intensifying.

Alkermes recently reported positive nine-month data from a long-term extension study of alixorexton, another OX2R agonist in late-stage development.

According to GlobalData senior healthcare researcher Irena Maragkou, Alkermes could challenge Takeda by offering a more convenient dosing schedule and potentially broader therapeutic use.

She also noted that increasing competition from other orexin receptor agonists and differences in patient response could influence Orzeyful’s long-term market position.

Meanwhile, Eli Lilly strengthened its position in the field by acquiring Centessa Pharmaceuticals for US$7.8 billion to gain access to its lead sleep-disorder candidate, cleminorexton, which has already achieved positive Phase II results across multiple sleep-wake disorders.